CSTL Stock Overview
A molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Castle Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.45 |
| 52 Week High | US$35.84 |
| 52 Week Low | US$16.97 |
| Beta | 0.98 |
| 11 Month Change | -10.73% |
| 3 Month Change | 3.34% |
| 1 Year Change | 43.32% |
| 33 Year Change | -36.58% |
| 5 Year Change | 5.18% |
| Change since IPO | 32.94% |
Recent News & Updates
Recent updates
Are Investors Undervaluing Castle Biosciences, Inc. (NASDAQ:CSTL) By 49%?
Oct 15
Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Castle Biosciences Q2 2022 Earnings Preview
Aug 08Shareholder Returns
| CSTL | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -10.5% | -1.2% | -1.0% |
| 1Y | 43.3% | 2.5% | 30.3% |
Return vs Industry: CSTL exceeded the US Healthcare industry which returned 1.1% over the past year.
Return vs Market: CSTL exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CSTL volatility | |
|---|---|
| CSTL Average Weekly Movement | 7.6% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CSTL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CSTL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 710 | Derek Maetzold | castlebiosciences.com |
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett’s esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder.
Castle Biosciences, Inc. Fundamentals Summary
| CSTL fundamental statistics | |
|---|---|
| Market cap | US$808.57m |
| Earnings (TTM) | US$6.08m |
| Revenue (TTM) | US$311.88m |
131.2x
P/E Ratio2.6x
P/S RatioIs CSTL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSTL income statement (TTM) | |
|---|---|
| Revenue | US$311.88m |
| Cost of Revenue | US$56.45m |
| Gross Profit | US$255.43m |
| Other Expenses | US$249.36m |
| Earnings | US$6.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 81.90% |
| Net Profit Margin | 1.95% |
| Debt/Equity Ratio | 2.3% |
How did CSTL perform over the long term?
See historical performance and comparison